
A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.


Advanced monitoring strategies are overcoming significant obstacles in retinal care, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

Advanced autofluorescence reveals cellular pigment reservoirs with therapeutic potential at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

This noninvasive imaging tool reveals early brain pathology through the eye, promising faster and more accurate diagnoses as highlighted at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Findings presented at the Heidelberg 2025 International SPECTRALIS Symposium — And Beyond (ISS) suggest detailed structural data could better inform therapeutic targeting and monitoring.

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, as shared at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer retinal disease, as presented at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

A panelist discusses how treating demodex blepharitis with Lotilaner not only eliminates the anterior blepharitis symptoms but also improves meibomian gland function, with low recurrence rates after treatment and significant benefits for patient comfort and quality of life.

A panelist discusses how demodex blepharitis frequently co-occurs with other ocular surface conditions in younger patients, as illustrated by a 35-year-old contact lens wearer who presented with recurrent styes, contact lens intolerance, and a history of rosacea.

A panelist discusses how treating ocular surface disease and demodex blepharitis before cataract surgery led to improved refractive measurements, resolved corneal staining, and enabled successful multifocal IOL implantation in a patient who had previously shown irregularly irregular topography patterns.

A panelist discusses how demodex blepharitis presents with distinctive symptoms like eyelash itching, colorettes at the base of lashes, and can significantly affect pre-surgical cataract measurements, requiring treatment before proceeding with surgery.

At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial.

At ARVO 2025, in Salt Lake City, Utah, Emma Lessieur-Contreras, MD, PhD, talked about her poster on retina extracellular vesicles, and the role that they play on diabetic retinopathy.




Deep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease.

At ARVO 2025, in Salt Lake City, Utah, Carly Lam, PhD, MSc, and Tsz Wing Leung, PhD talked about the evaluation of the visual performance of 2 modified DIMS spectacle lens designs.

Investigators were surprised by the outcome of a comparison between the Eyhance and enVista IOLs in low-light conditions.

Lori Wright, JD, sat down to talk about a discussion at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.

Early improvements in OSDI scores and tear osmolarity reinforce lifitegrast’s role in managing inflammation-driven dry eye disease.

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervals

A conversation with David S. Friedman, MD, PhD, on treating uncontrolled open-angle glaucoma in patients with limited options

A significant proportion of cataract surgery patients exhibit hyperosmolar tear film both before and 1 month after surgery, underscoring preoperative screening and postoperative management to optimize visual outcomes.

A panelist discusses how he managed a 57-year-old tennis player with dry eye and Hashimoto thyroiditis by selecting a Toric enVista IOL for her refractive lens exchange, noting the patient’s satisfaction despite a temporary market recall of the lens.

A panelist discusses how he successfully treated a complex case of a 72-year-old patient with previous radial keratotomy by using an innovative combination of an Apthera lens in the bag and a light adjustable lens in the sulcus as a primary piggyback.

A panelist discusses how ophthalmologists face challenges with Generation X patients who desire spectacle independence after laser vision correction, highlighting the difficulties in intraocular lens calculations and epithelial irregularities following previous refractive surgeries.

At ARVO 2025, in Salt Lake City, Utah, Steven Barnes, PhD, talked about his research on the OPA1 mutation in retinal ganglion cells' effect on the cell's electrical function.

At ARVO 2025, in Salt Lake City, Utah, Hsin-Yu Yang talked about the 9-month results from her study on the effectiveness of DIMS spectral lenses in myopic retardation for the pre-myopic preschoolers in Taiwan.